VIDEO: HOPE-3 bolsters primary prevention in intermediate-risk patients

CHICAGO – Results from the HOPE-3 trial confirm what guidelines have already recommended: patients with intermediate risk for cardiovascular disease should be treated for primary prevention of...
Source: Clinical Endocrinology News - Category: Endocrinology Source Type: news